|
rdf:type |
|
|
lifeskim:mentions |
umls-concept:C0021440,
umls-concept:C0030705,
umls-concept:C0082338,
umls-concept:C0201734,
umls-concept:C0205179,
umls-concept:C0205314,
umls-concept:C0205390,
umls-concept:C0538648,
umls-concept:C0585333,
umls-concept:C0677936,
umls-concept:C0679622,
umls-concept:C1521801,
umls-concept:C1527240,
umls-concept:C1883254
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2004-3-22
|
|
pubmed:abstractText |
TZT-1027 is a synthetic dolastatin 10 analog with antineoplastic properties in various cell lines and tumor xenografts. The purpose of this phase I study was to evaluate the safety and toxicity, maximum tolerated dose, pharmacokinetics and pharmacodynamics, clinical and metabolic antitumor activity of TZT-1027 when given as a 1-h intravenous infusion every 3 weeks in patients with refractory solid tumors.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Apr
|
|
pubmed:issn |
0923-7534
|
|
pubmed:author |
pubmed-author:AtsumiRR,
pubmed-author:BeuterAA,
pubmed-author:BolteOO,
pubmed-author:ChevertonPP,
pubmed-author:GanserAA,
pubmed-author:HofmannMM,
pubmed-author:JennerAA,
pubmed-author:OgumaTT,
pubmed-author:OttoDD,
pubmed-author:SatomiMM,
pubmed-author:SchöffskiPP,
pubmed-author:ThateBB,
pubmed-author:WandersJJ
|
|
pubmed:issnType |
Print
|
|
pubmed:volume |
15
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
671-9
|
|
pubmed:dateRevised |
2007-11-15
|
|
pubmed:meshHeading |
pubmed-meshheading:15033678-Adult,
pubmed-meshheading:15033678-Aged,
pubmed-meshheading:15033678-Alopecia,
pubmed-meshheading:15033678-Anorexia,
pubmed-meshheading:15033678-Antineoplastic Agents,
pubmed-meshheading:15033678-Area Under Curve,
pubmed-meshheading:15033678-Constipation,
pubmed-meshheading:15033678-Depsipeptides,
pubmed-meshheading:15033678-Dose-Response Relationship, Drug,
pubmed-meshheading:15033678-Fatigue,
pubmed-meshheading:15033678-Female,
pubmed-meshheading:15033678-Humans,
pubmed-meshheading:15033678-Infusions, Intravenous,
pubmed-meshheading:15033678-Leukopenia,
pubmed-meshheading:15033678-Male,
pubmed-meshheading:15033678-Middle Aged,
pubmed-meshheading:15033678-Nausea,
pubmed-meshheading:15033678-Neoplasms,
pubmed-meshheading:15033678-Neutropenia,
pubmed-meshheading:15033678-Oligopeptides
|
|
pubmed:year |
2004
|
|
pubmed:articleTitle |
Phase I and pharmacokinetic study of TZT-1027, a novel synthetic dolastatin 10 derivative, administered as a 1-hour intravenous infusion every 3 weeks in patients with advanced refractory cancer.
|
|
pubmed:affiliation |
Department of Hematology and Oncology, Hannover Medical School, Hannover, Germany. schoeffski.patrick@mh-hannover.de
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase I
|
